BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23948956)

  • 1. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.
    Abd Al Kader L; Oka T; Takata K; Sun X; Sato H; Murakami I; Toji T; Manabe A; Kimura H; Yoshino T
    Virchows Arch; 2013 Nov; 463(5):697-711. PubMed ID: 23948956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
    Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
    Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma.
    van Kemenade FJ; Raaphorst FM; Blokzijl T; Fieret E; Hamer KM; Satijn DP; Otte AP; Meijer CJ
    Blood; 2001 Jun; 97(12):3896-901. PubMed ID: 11389032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
    Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
    J Virol; 2019 May; 93(9):. PubMed ID: 30814291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
    Tian X; Pelton A; Shahsafaei A; Dorfman DM
    Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
    Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
    Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
    Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
    Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene.
    Raaphorst FM; Meijer CJ; Fieret E; Blokzijl T; Mommers E; Buerger H; Packeisen J; Sewalt RA; Otte AP; van Diest PJ
    Neoplasia; 2003; 5(6):481-8. PubMed ID: 14965441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
    Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
    Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.
    Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC
    Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.
    Lee SC; Phipson B; Hyland CD; Leong HS; Allan RS; Lun A; Hilton DJ; Nutt SL; Blewitt ME; Smyth GK; Alexander WS; Majewski IJ
    Blood; 2013 Oct; 122(15):2654-63. PubMed ID: 23982173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
    Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
    Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.
    Tian X; Xu J; Dorfman DM
    Am J Surg Pathol; 2019 Jan; 43(1):102-109. PubMed ID: 30371509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
    Ha SY; Kim SH
    Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines.
    Dukers DF; van Galen JC; Giroth C; Jansen P; Sewalt RG; Otte AP; Kluin-Nelemans HC; Meijer CJ; Raaphorst FM
    Am J Pathol; 2004 Mar; 164(3):873-81. PubMed ID: 14982841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.
    Visser HP; Gunster MJ; Kluin-Nelemans HC; Manders EM; Raaphorst FM; Meijer CJ; Willemze R; Otte AP
    Br J Haematol; 2001 Mar; 112(4):950-8. PubMed ID: 11298590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease.
    Raaphorst FM; van Kemenade FJ; Blokzijl T; Fieret E; Hamer KM; Satijn DP; Otte AP; Meijer CJ
    Am J Pathol; 2000 Sep; 157(3):709-15. PubMed ID: 10980109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).
    Changchien YC; Tátrai P; Papp G; Sápi J; Fónyad L; Szendrői M; Pápai Z; Sápi Z
    J Transl Med; 2012 Oct; 10():216. PubMed ID: 23110793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
    Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
    Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.